By Benjamin Chiou
Date: Monday 13 Oct 2025
(Sharecast News) - IP Group said it is "encouraged" by the results of a recent clinical trial of a Metsara obesity drug, which could result in future sustainable royalties if approved by regulators.
The company, which invests in early stage businesses in the deeptech, life sciences and cleantech sectors, owns and...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news